A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Identifieur interne : 004518 ( PubMed/Checkpoint ); précédent : 004517; suivant : 004519A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Auteurs : R B Dewey [États-Unis] ; D M Maraganore ; J E Ahlskog ; J Y MatsumotoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- Administration, Intranasal, Aerosols, Aged, Antiemetics (administration & dosage), Antiemetics (adverse effects), Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Apomorphine (administration & dosage), Apomorphine (adverse effects), Benzamides (administration & dosage), Benzamides (adverse effects), Cross-Over Studies, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Pilot Projects, Premedication, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiemetics, Antiparkinson Agents, Apomorphine, Benzamides, Levodopa.
- chemical , adverse effects : Antiemetics, Antiparkinson Agents, Apomorphine, Benzamides, Levodopa.
- chemical : Aerosols.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- Administration, Intranasal, Aged, Cross-Over Studies, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Premedication, Treatment Outcome.
Abstract
Nine patients with advanced levodopa-responsive Parkinson's disease were enrolled in a double-blind, placebo-controlled crossover trial of intranasal apomorphine as rescue therapy for parkinsonian off-states. Patients were assigned in random order to each of four possible combinations of apomorphine, trimethobenzamide antiemetic, and their matched placebos and received detailed in-office motor scoring during each of the four study periods. Patients also completed diaries describing the effectiveness of the nasal spray for reversing off-states. A statistically significant reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score was seen following active apomorphine during in-office evaluation visits but not following placebo nasal spray. Patient diaries revealed that active apomorphine had a latency to onset of 11 minutes and a duration of 50 minutes. Significant nausea from apomorphine spray was seen in only one patient whereas nasal irritation was disabling in three and mild in two. We conclude that intranasal apomorphine is an effective rescue agent for parkinsonian off-states although nasal irritation is a limiting factor.
DOI: 10.1002/mds.870130505
PubMed: 9756146
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9756146Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.</title>
<author><name sortKey="Dewey, R B" sort="Dewey, R B" uniqKey="Dewey R" first="R B" last="Dewey">R B Dewey</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas 75235-8897, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Texas Southwestern Medical School, Dallas 75235-8897</wicri:regionArea>
<wicri:noRegion>Dallas 75235-8897</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Maraganore, D M" sort="Maraganore, D M" uniqKey="Maraganore D" first="D M" last="Maraganore">D M Maraganore</name>
</author>
<author><name sortKey="Ahlskog, J E" sort="Ahlskog, J E" uniqKey="Ahlskog J" first="J E" last="Ahlskog">J E Ahlskog</name>
</author>
<author><name sortKey="Matsumoto, J Y" sort="Matsumoto, J Y" uniqKey="Matsumoto J" first="J Y" last="Matsumoto">J Y Matsumoto</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9756146</idno>
<idno type="pmid">9756146</idno>
<idno type="doi">10.1002/mds.870130505</idno>
<idno type="wicri:Area/PubMed/Corpus">004338</idno>
<idno type="wicri:Area/PubMed/Curation">004338</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004518</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.</title>
<author><name sortKey="Dewey, R B" sort="Dewey, R B" uniqKey="Dewey R" first="R B" last="Dewey">R B Dewey</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas 75235-8897, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Texas Southwestern Medical School, Dallas 75235-8897</wicri:regionArea>
<wicri:noRegion>Dallas 75235-8897</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Maraganore, D M" sort="Maraganore, D M" uniqKey="Maraganore D" first="D M" last="Maraganore">D M Maraganore</name>
</author>
<author><name sortKey="Ahlskog, J E" sort="Ahlskog, J E" uniqKey="Ahlskog J" first="J E" last="Ahlskog">J E Ahlskog</name>
</author>
<author><name sortKey="Matsumoto, J Y" sort="Matsumoto, J Y" uniqKey="Matsumoto J" first="J Y" last="Matsumoto">J Y Matsumoto</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term>
<term>Aerosols</term>
<term>Aged</term>
<term>Antiemetics (administration & dosage)</term>
<term>Antiemetics (adverse effects)</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Apomorphine (administration & dosage)</term>
<term>Apomorphine (adverse effects)</term>
<term>Benzamides (administration & dosage)</term>
<term>Benzamides (adverse effects)</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Pilot Projects</term>
<term>Premedication</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiemetics</term>
<term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Benzamides</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiemetics</term>
<term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Benzamides</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Aerosols</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Premedication</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nine patients with advanced levodopa-responsive Parkinson's disease were enrolled in a double-blind, placebo-controlled crossover trial of intranasal apomorphine as rescue therapy for parkinsonian off-states. Patients were assigned in random order to each of four possible combinations of apomorphine, trimethobenzamide antiemetic, and their matched placebos and received detailed in-office motor scoring during each of the four study periods. Patients also completed diaries describing the effectiveness of the nasal spray for reversing off-states. A statistically significant reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score was seen following active apomorphine during in-office evaluation visits but not following placebo nasal spray. Patient diaries revealed that active apomorphine had a latency to onset of 11 minutes and a duration of 50 minutes. Significant nausea from apomorphine spray was seen in only one patient whereas nasal irritation was disabling in three and mild in two. We conclude that intranasal apomorphine is an effective rescue agent for parkinsonian off-states although nasal irritation is a limiting factor.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9756146</PMID>
<DateCreated><Year>1999</Year>
<Month>01</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted><Year>1999</Year>
<Month>01</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>5</Issue>
<PubDate><Year>1998</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>782-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Nine patients with advanced levodopa-responsive Parkinson's disease were enrolled in a double-blind, placebo-controlled crossover trial of intranasal apomorphine as rescue therapy for parkinsonian off-states. Patients were assigned in random order to each of four possible combinations of apomorphine, trimethobenzamide antiemetic, and their matched placebos and received detailed in-office motor scoring during each of the four study periods. Patients also completed diaries describing the effectiveness of the nasal spray for reversing off-states. A statistically significant reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score was seen following active apomorphine during in-office evaluation visits but not following placebo nasal spray. Patient diaries revealed that active apomorphine had a latency to onset of 11 minutes and a duration of 50 minutes. Significant nausea from apomorphine spray was seen in only one patient whereas nasal irritation was disabling in three and mild in two. We conclude that intranasal apomorphine is an effective rescue agent for parkinsonian off-states although nasal irritation is a limiting factor.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dewey</LastName>
<ForeName>R B</ForeName>
<Initials>RB</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo><Affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas 75235-8897, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Maraganore</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ahlskog</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Matsumoto</LastName>
<ForeName>J Y</ForeName>
<Initials>JY</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000932">Antiemetics</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber>
<NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W2X096QY97</RegistryNumber>
<NameOfSubstance UI="C100146">trimethobenzamide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000281">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000336">Aerosols</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000932">Antiemetics</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011292">Premedication</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>2</Hour>
<Minute>3</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2001</Year>
<Month>3</Month>
<Day>28</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1998</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>2</Hour>
<Minute>3</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">9756146</ArticleId>
<ArticleId IdType="doi">10.1002/mds.870130505</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><noCountry><name sortKey="Ahlskog, J E" sort="Ahlskog, J E" uniqKey="Ahlskog J" first="J E" last="Ahlskog">J E Ahlskog</name>
<name sortKey="Maraganore, D M" sort="Maraganore, D M" uniqKey="Maraganore D" first="D M" last="Maraganore">D M Maraganore</name>
<name sortKey="Matsumoto, J Y" sort="Matsumoto, J Y" uniqKey="Matsumoto J" first="J Y" last="Matsumoto">J Y Matsumoto</name>
</noCountry>
<country name="États-Unis"><noRegion><name sortKey="Dewey, R B" sort="Dewey, R B" uniqKey="Dewey R" first="R B" last="Dewey">R B Dewey</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004518 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004518 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:9756146 |texte= A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9756146" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |